Menu
X

China’s New CAR-T Therapy ssCART-19: Exceptional Safety with Zero ICANS Incidence

China’s New CAR-T Therapy ssCART-19: Exceptional Safety with Zero ICANS Incidence

CARTTherapy

CARTTherapy

#ssCART19 #CAR_T #CART #ALL #ICANS #CNSL #CARTTherapy

CAR-T therapy has reached another breakthrough with the introduction of ssCART-19, a new treatment that leverages IL-6 gene silencing technology to significantly reduce side effects, particularly when treating relapsed/refractory acute lymphoblastic leukemia (r/r ALL). Unlike traditional CAR-T therapies, ssCART-19 drastically lowers the risks of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

In the latest clinical trials, ssCART-19 demonstrated outstanding safety, with no patients experiencing ICANS, marking a milestone in CAR-T therapy safety. Among the 17 patients treated, 58.8% showed a significant increase in cell counts, and no cases of Grade 4 or higher CRS were reported. Additionally, ssCART-19 achieved an overall response rate (ORR) of 87.5% within three months, with nearly 63% of patients reaching complete remission.

The latest research also highlights that ssCART-19 outperforms traditional CAR-T products (cCART-19) in both safety and efficacy. Compared to conventional therapies, ssCART-19 significantly reduced the incidence of severe CRS, neutropenia, and ICANS, achieving an ORR of 91.5%. With these impressive results, ssCART-19 is expected to become a groundbreaking option for treating r/r ALL, offering new hope, especially for patients with central nervous system leukemia (CNSL).

Developed by a Chinese biopharmaceutical company, ssCART-19 has gained widespread recognition on the international stage, receiving Orphan Drug designation from the U.S. FDA and being listed as a breakthrough therapy in China. ssCART-19 offers a new treatment option for patients previously excluded from CAR-T therapy, greatly enhancing their chances of survival.

Stay tuned for more updates on how ssCART-19 is transforming cancer immunotherapy.

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.